keyword
MENU ▼
Read by QxMD icon Read
search

Metastatic pancreatic cancer

keyword
https://www.readbyqxmd.com/read/29928669/cholecystokinin-receptor-targeted-polyplex-nanoparticle-inhibits-growth-and-metastasis-of-pancreatic-cancer
#1
Julian Burks, Sandeep Nadella, Abdullah Mahmud, Charoen Mankongpaisarnrung, Juan Wang, Jong-In Hahm, Robin D Tucker, Narayan Shivapurkar, Stephan T Stern, Jill P Smith
Background & Aims: Pancreatic ductal adenocarcinoma (PDAC) remains the most aggressive malignancy with the lowest 5-year survival rate of all cancers in part owing to the lack of tumor-specific therapy and the rapid metastatic nature of this cancer. The gastrointestinal peptide gastrin is a trophic peptide that stimulates growth of PDAC in an autocrine fashion by interaction with the cholecystokinin receptor that is overexpressed in this malignancy. Methods: We developed a therapeutic novel polyplex nanoparticle (NP) that selectively targets the cholecystokinin receptor on PDAC...
2018: Cellular and Molecular Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29928492/liquid-biopsy-in-pancreatic-cancer-the-beginning-of-a-new-era
#2
REVIEW
Dipesh Kumar Yadav, Xueli Bai, Rajesh Kumar Yadav, Alina Singh, Guogang Li, Tao Ma, Wei Chen, Tingbo Liang
With dismal survival rate pancreatic cancer remains one of the most aggressive and devastating malignancy. Predominantly, due to the absence of a dependable methodology for early identification and limited therapeutic options for advanced disease. However, it takes over 17 years to develop pancreatic cancer from initiation of mutation to metastatic cancer; therefore, if diagnosed early; it may increase overall survival dramatically, thus, providing a window of opportunity for early detection. Recently, genomic expression analysis defined 4 subtypes of pancreatic cancer based on mutated genes...
June 1, 2018: Oncotarget
https://www.readbyqxmd.com/read/29922073/identification-of-pgam1-as-a-putative-therapeutic-target-for-pancreatic-ductal-adenocarcinoma-metastasis-using-quantitative-proteomics
#3
Xinlu Liu, Yejing Weng, Peng Liu, Zhigang Sui, Lei Zhou, Yinpeng Huang, Lihua Zhang, Yukui Zhang, Xiaodong Tan
Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive gastrointestinal cancer characterized by an extremely low survival rate because of early metastasis. Identifying satisfactory therapeutic targets associated with metastasis is crucial to improve the treatment effect of PDAC. Materials and methods: In this research, we used stable isotope labeling by amino acids in cell culture, 1-dodecyl-3-methylimidazolium chloride-assisted sample preparation method preparing protein sample and nano-reversed-phase liquid chromatography-mass spectrometry/mass spectrometry analysis to perform the comparative proteomics of two homologous hamster pancreatic cancer cell lines that are different in metastatic ability: PC-1...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29921500/measurement-of-copy-number-of-actn4-to-optimize-the-therapeutic-strategy-for-locally-advanced-pancreatic-cancer
#4
REVIEW
Hirokazu Shoji, Nami Miura, Hideki Ueno, Kazufumi Honda
The standard therapeutic strategy recommended for locally advanced pancreatic cancer (LAPC) is typically chemotherapy or chemoradiotherapy (CRT). Although the clinical benefit of chemotherapy alone versus CRT for LAPC has been compared in a number of clinical trials, the optimal therapy for LAPC remains unclear. Moreover, the clinical benefit derived from treatment in each clinical trial is a matter of controversy, and the superiority of one treatment over another has yet to be definitively demonstrated. The poor outcomes seen among patients with LAPC owe largely to the emergence of metastatic disease; therefore, accurately evaluating occult distant metastasis before choosing a therapeutic strategy could be expected to help stratify patients with LAPC into the most appropriate treatment regimen, namely local control or systemic therapy...
June 16, 2018: Pancreatology: Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]
https://www.readbyqxmd.com/read/29920275/regulation-of-epithelial-plasticity-determines-metastatic-organotropism-in-pancreatic-cancer
#5
Maximilian Reichert, Basil Bakir, Leticia Moreira, Jason R Pitarresi, Karin Feldmann, Lauren Simon, Kensuke Suzuki, Ravikanth Maddipati, Andrew D Rhim, Anna M Schlitter, Mark Kriegsmann, Wilko Weichert, Matthias Wirth, Kathleen Schuck, Günter Schneider, Dieter Saur, Albert B Reynolds, Andres J Klein-Szanto, Burcin Pehlivanoglu, Bahar Memis, N Volkan Adsay, Anil K Rustgi
The regulation of metastatic organotropism in pancreatic ductal a denocarcinoma (PDAC) remains poorly understood. We demonstrate, using multiple mouse models, that liver and lung metastatic organotropism is dependent upon p120catenin (p120ctn)-mediated epithelial identity. Mono-allelic p120ctn loss accelerates KrasG12D -driven pancreatic cancer formation and liver metastasis. Importantly, one p120ctn allele is sufficient for E-CADHERIN-mediated cell adhesion. By contrast, cells with bi-allelic p120ctn loss demonstrate marked lung organotropism; however, rescue with p120ctn isoform 1A restores liver metastasis...
June 18, 2018: Developmental Cell
https://www.readbyqxmd.com/read/29920271/emt-in-metastasis-finding-the-right-balance
#6
Hin Ching Lo, Xiang H-F Zhang
The epithelial-to-mesenchymal transition (EMT) is a key driver of cancer metastasis. In this issue of Developmental Cell, Aiello et al. (2018) demonstrate that an EMT mechanism involving protein internalization impacts cell migration, while Reichert et al. (2018) identify epithelial plasticity as a determinant of metastatic organotropism in pancreatic cancer.
June 18, 2018: Developmental Cell
https://www.readbyqxmd.com/read/29914752/improving-the-accuracy-of-pancreatic-cancer-clinical-staging-by-exploitation-of-nanoparticle-blood-interactions-a-pilot-study
#7
D Caputo, M Cartillone, C Cascone, D Pozzi, L Digiacomo, S Palchetti, G Caracciolo, R Coppola
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) early diagnosis is  crucial  and new, cheap and user-friendly techniques for biomarker identification  are  needed. "Protein corona" (PC) is emerging a new bio-interface potentially useful in tumor early diagnosis. In a previous investigation, we showed that relevant differences between the  protein patterns of  PCs formed on lipid NPs after exposure to PDAC and non-cancer plasma  samples exist. To extend that research, We performed this pilot study to investigate the effect of PDAC tumor size and distant metastases on PC composition...
June 12, 2018: Pancreatology: Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]
https://www.readbyqxmd.com/read/29910636/performance-status-dynamics-during-treatment-with-nab-paclitaxel-plus-gemcitabine-versus-gemcitabine-alone-for-metastatic-pancreatic-cancer
#8
E Gabriela Chiorean, Daniel Von Hoff, Yin Wan, Sandra Margunato-Debay, Marc Botteman, David Goldstein
Objectives: This analysis examined changes in Karnofsky performance status (KPS) as a surrogate for patient's well-being during treatment with nab -paclitaxel plus gemcitabine vs gemcitabine alone as first-line therapy for metastatic pancreatic cancer (MPC) in the Phase III MPACT trial. Participants and methods: Descriptive analyses were performed for KPS at three time points (3 and 6 months after randomization and 1 month before disease progression) and for time to any KPS deterioration...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29903049/the-hepatic-pre-metastatic-niche-in-pancreatic-ductal-adenocarcinoma
#9
REVIEW
Demi S Houg, Maarten F Bijlsma
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies to date, largely because it is associated with high metastatic risk. Pancreatic tumors have a characteristic tendency to metastasize preferentially to the liver. Over the past two decades, it has become evident that the otherwise hostile milieu of the liver is selectively preconditioned at an early stage to render it more conducive to the engraftment and growth of disseminated cancer cells, a concept defined as pre-metastatic niche (PMN) formation...
June 14, 2018: Molecular Cancer
https://www.readbyqxmd.com/read/29898439/the-diagnostic-accuracy-of-cytology-for-the-diagnosis-of-hepatobiliary-and-pancreatic-cancers
#10
Marwan Al-Hajeili, Maryam Alqassas, Astabraq Alomran, Bashaer Batarfi, Bashaer Basunaid, Reem Alshail, Shahad Alaydarous, Rana Bokhary, Mahmoud Mosli
OBJECTIVE: Although cytology testing is considered a valuable method to diagnose tumors that are difficult to access such as hepato-biliary-pancreatic (HBP) malignancies, its diagnostic accuracy remains unclear. We therefore aimed to investigate the diagnostic accuracy of cytology testing for HBP tumors. STUDY DESIGN: We performed a retrospective study of all cytology samples that were used to confirm radiologically detected HBP tumors between 2002 and 2016. The cytology techniques used in our center included fine needle aspiration (FNA), brush cytology, and aspiration of bile...
June 13, 2018: Acta Cytologica
https://www.readbyqxmd.com/read/29898269/metastatic-pancreatic-ductal-adenocarcinoma-diagnosis-and-treatment-with-a-view-to-the-future
#11
Adrian M J Pokorny, Venessa T Chin, Adnan M Nagrial, Desmond Yip, Lorraine A Chantrill
Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a lethal disease with a poor 5-year survival. Systemic treatments can be used to control symptoms and prolong life. Cytotoxic chemotherapies are commonly administered, with combination treatments, such as fluorouracil, folinic acid, irinotecan and oxaliplatin (FOLFIRINOX) or nab-paclitaxel and gemcitabine showing the largest clinical benefits. Newer genomic classifications of PDAC may provide a rationale for targeted therapies or immunotherapies, although at present these remain largely experimental...
June 2018: Internal Medicine Journal
https://www.readbyqxmd.com/read/29896283/from-first-line-to-sequential-treatment-in-the-management-of-metastatic-pancreatic-cancer
#12
REVIEW
Andrés Muñoz Martín, Manuel Hidalgo, Rafael Alvarez, Virginia Arrazubi, Joaquina Martínez-Galán, Mercedes Salgado, Teresa Macarulla, Alfredo Carrato
The current management of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) is based on systemic chemotherapy. The results of the MPACT and PRODIGE clinical trials have demonstrated that the combination of nab-paclitaxel and gemcitabine (GEM) as well as FOLFIRINOX regimen result in improvement in overall survival when compared to GEM alone. Treatment guidelines now recommend either one of these two regimens as first line treatment for fit patients with mPDAC. Because no head-to-head comparison between the two regimens exists, the selection of one versus the other is based on clinical criteria...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29895293/robotic-treatment-of-oligometastatic-kidney-tumor-with-synchronous-pancreatic-metastasis-case-report-and-review-of-the-literature
#13
Andrea Boni, Giovanni Cochetti, Stefano Ascani, Michele Del Zingaro, Francesca Quadrini, Alessio Paladini, Diego Cocca, Ettore Mearini
BACKGROUND: The management of metastatic Renal Cell Carcinoma (RCC) has changed dramatically in the last 20 years, and the role of surgery in the immunotherapy's era is under debate. Metastatic lesions interesting pancreas are infrequent, but those harbouring from RCC have an high incidence. If metachronous resections are not rare, synchronous resection of primary RCC and its pancreatic metastasis is uncommonly reported, and accounts for a bad prognosis. CASE PRESENTATION: We report the case of a 68 years old woman, who presented hematuria at hospital incoming, with radiological appearance of a 13 cm left renal mass, with a 2...
June 13, 2018: BMC Surgery
https://www.readbyqxmd.com/read/29891522/clinical-impact-of-local-progression-in-pancreatic-cancer
#14
Nicholas Cardillo, Daniel M Seible, Katherine E Fero, Andrew R Bruggeman, Reith R Sarkar, Alexa Azuara, Daniel R Simpson, James D Murphy
Background: The high prevalence of distant metastatic disease among patients with pancreatic cancer often draws attention away from the local pancreatic tumor. This study aimed to define the complications and hospitalizations from local versus distant disease progression among a retrospective cohort of patients with pancreatic cancer. Methods: Records of 298 cases of pancreatic cancer treated at a single institution from 2004 through 2015 were retrospectively reviewed, and cancer-related symptoms and complications requiring hospitalization were recorded...
June 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29890560/sequence-therapy-in-metastatic-pancreatic-cancer
#15
Oliver Waidmann, Uwe Pelzer, Stefan Boeck, Dirk-Thomas Waldschmidt
Pancreatic cancer is one of the most lethal cancer diseases. For years, gemcitabine has been the standard of care and the only therapeutic option in patients with metastatic pancreatic cancer. Within the last years, new combination therapies have been established for first-line treatment, which significantly improve overall survival in comparison to gemcitabine monotherapy. Furthermore, new second-line therapies have been identified, which significantly improve overall survival. The current manuscript summarizes briefly standard of care first- and second-line chemotherapies and discusses possible treatment sequences...
June 2018: Zeitschrift Für Gastroenterologie
https://www.readbyqxmd.com/read/29882080/s-1-induced-discoid-lupus-erythematosus-like-lesions-and-long-term-complete-response-for-para-aortic-lymph-node-recurrence-of-pancreatic-ductal-adenocarcinoma-a-case-report
#16
Ryosuke Yamaga, Koji Tezuka, Shuichiro Sugawara, Toshihiro Watanabe, Ichiro Hirai, Tamio Suzuki, Wataru Kimura
BACKGROUND: Metastatic recurrence after resection of pancreatic cancer is considered to be an incurable disease, and discoid lupus erythematosus (DLE)-like lesions are known as a side effect of fluorouracil agents. We report a very rare case of metastatic recurrence of pancreatic cancer in a Japanese man with DLE-like lesions in which long-term complete response was achieved through S-1 monotherapy. CASE PRESENTATION: A 65-year-old man who had undergone distal pancreatectomy with splenectomy for pancreatic body cancer and had received adjuvant gemcitabine developed postoperative para-aortic lymph node recurrence 17 months after surgery...
June 7, 2018: Surgical Case Reports
https://www.readbyqxmd.com/read/29880482/hypoxic-tumor-derived-exosomal-mir-301a-mediates-m2-macrophage-polarization-via-pten-pi3k%C3%AE-to-promote-pancreatic-cancer-metastasis
#17
Xiaofeng Wang, Guangtao Luo, Kundong Zhang, Jun Cao, Chen Huang, Tao Jiang, Bingya Liu, Liping Su, Zhengjun Qiu
Exosomes are emerging as important mediators of the crosstalk between tumor cells and the microenvironment. However, the mechanisms by which exosomes modulate tumor development under hypoxia in pancreatic cancer (PC) remain largely unknown. Here we found that hypoxic exosomes derived from PC cells activate macrophages to the M2 phenotype in a HIF-1a or HIF-2a-dependent manner, which then facilitates the migration, invasion, and EMT of PC cells. Given that exosomes have been shown to transport miRNAs to alter cellular functions, we discovered that miR-301a-3p was highly expressed in hypoxic PC cells and enriched in hypoxic PC cells-derived exosomes...
June 7, 2018: Cancer Research
https://www.readbyqxmd.com/read/29875415/the-benefits-of-modified-folfirinox-for-advanced-pancreatic-cancer-and-its-induced-adverse-events-a-systematic-review-and-meta-analysis
#18
Hongxuan Tong, Zhu Fan, Biyuan Liu, Tao Lu
FOLFIRINOX has been one of the first-line options for advanced pancreatic cancer, even though it induces significant adverse effects. Several institutions have begun using modified FOLFIRINOX to decrease its side effects and increase its tolerability. We systematically investigated the outcome from patients who initially received modified FOLFIRINOX as a chemotherapy regimen for advanced pancreatic cancer. We used the random-model generic inverse variance method to analyse the binary data with 95% confidence intervals (CIs)...
June 6, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29872721/vasodilator-stimulated-phosphoprotein-promotes-liver-metastasis-of-gastrointestinal-cancer-by-activating-a-%C3%AE-1-integrin-fak-yap1-taz-signaling-pathway
#19
Xiaoyu Xiang, Yuanguo Wang, Hongbin Zhang, Jinhua Piao, Selvaraj Muthusamy, Lei Wang, Yibin Deng, Wei Zhang, Rui Kuang, Daniel D Billadeau, Shengbing Huang, Jinping Lai, Raul Urrutia, Ningling Kang
Extracellular matrix (ECM)-induced β1-integrin-FAK signaling promotes cell attachment, survival, and migration of cancer cells in a distant organ so as to enable cancer metastasis. However, mechanisms governing activation of the β1-integrin-FAK signaling remain incompletely understood. Here, we report that vasodilator-stimulated phosphoprotein (VASP), an actin binding protein, is required for ECM-mediated β1-integrin-FAK-YAP1/TAZ signaling in gastrointestinal (GI) cancer cells and their liver metastasis...
2018: NPJ Precision Oncology
https://www.readbyqxmd.com/read/29869381/a-single-index-threshold-cox-proportional-hazard-model-for-identifying-a-treatment-sensitive-subset-based-on-multiple-biomarkers
#20
Ye He, Huazhen Lin, Dongsheng Tu
In this paper, we introduce a single-index threshold Cox proportional hazard model to select and combine biomarkers to identify patients who may be sensitive to a specific treatment. A penalized smoothed partial likelihood is proposed to estimate the parameters in the model. A simple, efficient, and unified algorithm is presented to maximize this likelihood function. The estimators based on this likelihood function are shown to be consistent and asymptotically normal. Under mild conditions, the proposed estimators also achieve the oracle property...
June 4, 2018: Statistics in Medicine
keyword
keyword
31154
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"